Wedbush Expects Increased Earnings for Tango Therapeutics

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Investment analysts at Wedbush lifted their FY2025 EPS estimates for Tango Therapeutics in a research note issued to investors on Tuesday, November 4th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.86) per share for the year, up from their previous estimate of ($1.35). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Wedbush also issued estimates for Tango Therapeutics’ Q4 2025 earnings at ($0.28) EPS, Q1 2026 earnings at ($0.28) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at ($0.07) EPS.

Other equities analysts also recently issued reports about the company. Piper Sandler initiated coverage on Tango Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $11.00 price objective for the company. Guggenheim lifted their target price on Tango Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research note on Monday, October 27th. Wall Street Zen raised Tango Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tango Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Tango Therapeutics Trading Down 1.7%

NASDAQ TNGX opened at $7.87 on Friday. The company has a 50-day moving average price of $7.71 and a two-hundred day moving average price of $5.64. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $9.70. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -8.46 and a beta of 1.66.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.12. The business had revenue of $53.81 million for the quarter, compared to analysts’ expectations of $41.35 million. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 60.80%.

Insider Activity at Tango Therapeutics

In other news, major shareholder Rock Ventures Iv L.P. Third sold 477,401 shares of the company’s stock in a transaction on Thursday, October 23rd. The stock was sold at an average price of $10.15, for a total value of $4,845,620.15. Following the completion of the sale, the insider owned 13,386,574 shares in the company, valued at $135,873,726.10. This represents a 3.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 3,472,501 shares of company stock valued at $26,350,320. 7.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TNGX. CWM LLC raised its position in Tango Therapeutics by 182.2% in the second quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after acquiring an additional 3,167 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Tango Therapeutics by 78.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after purchasing an additional 3,452 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Tango Therapeutics by 44.3% during the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $49,000 after purchasing an additional 2,907 shares during the last quarter. Finally, Northeast Financial Consultants Inc acquired a new stake in Tango Therapeutics during the second quarter valued at approximately $51,000. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.